Market Place
Sourcing Support
All News #Library
Biotech
Actinium Pharma Reveal Radiotherapy Platform Breakthrough at AACR
10 Apr 2026 //
INDPHARMAPOST
Actinium Pharma To Present 2 Abstracts At 2026 AACR Meeting
17 Feb 2026 //
PR NEWSWIRE
Actinium Pharma Shows ATNM-400`s Strong Anti-Tumor Activity
12 Dec 2025 //
PR NEWSWIRE
Actinium Reveals ATNM-400`s Strong Efficacy in Breast Cancer
01 Dec 2025 //
PR NEWSWIRE
Actinium Pharma To Present ATNM-400 Data In Breast Cancer
04 Nov 2025 //
PR NEWSWIRE
Actinium Pharma Joins Stephens Biotech Virtual Fireside Chat
03 Nov 2025 //
PR NEWSWIRE
Actinium Showcases ATNM-400 Preclinical Data For Prostate Cancer
13 Oct 2025 //
PR NEWSWIRE
Actinium Reveals ATNM-400`s Superior Efficacy in Prostate Cancer
31 Jul 2025 //
PR NEWSWIRE
Actinium Hosts KOL Investor Call On Revamped Clinical Strategy
25 Mar 2025 //
PR NEWSWIRE
Actinium Pharma Announces Trial Program in Solid Tumors Combining Actimab-A
18 Mar 2025 //
PR NEWSWIRE
Actinium Pharmaceuticals Announces Actimab-A + CLAG-M Trial Result
17 Mar 2025 //
PR NEWSWIRE
Actinium Publishes Results from the Phase 3 SIERRA Trial of Iomab-
20 Sep 2024 //
PR NEWSWIRE
Actinium Updates On Iomab-B BLA Filing And Future US Plans
05 Aug 2024 //
PR NEWSWIRE
Actinium To Host KOL Webinar On Iomab-ACT CAR-T Trial Design
15 May 2024 //
PR NEWSWIRE
Actinium Presents TP53+ Survival, Iomab-B Long-Term Data At EHA 2024
14 May 2024 //
PR NEWSWIRE
Actinium Webinar On Iomab-ACT CAR-T Trial At UT Southwestern
07 May 2024 //
PR NEWSWIRE
Actinium Announces Trial to Study with Leading FDA-Approved CAR T-Cell Therapy
26 Mar 2024 //
PR NEWSWIRE
Actinium Announces Iomab-B Markedly Increases Long Term Survival in AML
26 Feb 2024 //
PR NEWSWIRE
Actinium Presents Data Showing Actimab-A`s Potential to Restore T Cell Immunity
06 Nov 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.